Washington University School of Medicine - Siteman Cancer Center
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States19 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07421700 | |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Clear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07227415 | |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT07227012 | |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, liposarcoma, myomatous neoplasm, neoplasm, retroperitoneal sarcoma, sarcoma | Recruiting | Phase 3 | 2026-10-07 | NCT04031677 | |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT06500273 | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Disease Attributes, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT03970447 | |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-29 | NCT06881784 | |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | Small Cell Lung Cancer Extensive Stage | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT05703971 | |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-04 | NCT07361562 | |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT05548127 | |
| A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, skin disorder, uterine disorder | Recruiting | Phase 1 | 2026-08-26 | NCT07383506 | |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-23 | NCT05957367 | |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, digestive system disorder, digestive system neoplasm, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, skin disorder, stomach disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-07-22 | NCT06157892 | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04404283 | |
| Study of Novel Treatment Combinations in Patients With Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-06-01 | NCT05633667 | |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-05-19 | NCT06760637 | |
| Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 2 | 2026-04-28 | NCT03964727 | |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-09 | NCT05573555 | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Active, not recruiting | Phase 3 | 2026-02-05 | NCT03673501 |